长期抗凝患者初次全膝关节置换术后给予美洛昔康或塞来昔布是否安全
基于行政索赔数据库回顾232,542例2017至2021年全膝关节置换术患者,其中2,299例长期抗凝、508例术后处方塞来昔布或美洛昔康;联合使用NSAIDs未增加输血和再入院风险,与手法松解减少相关(OR 0.48),且90天和180天阿片类药物处方填充略有减少。
要点
- 长期抗凝患者TKA术后使用塞来昔布或美洛昔康未增加30、90、180天输血和再入院风险。
- 抗凝患者使用NSAIDs后90天(9%,P=0.038)和180天(10%,P=0.040)阿片类药物处方填充略有减少。
核心结论
- 长期抗凝患者初次TKA术后联合使用COX-2 NSAIDs未增加输血或再入院风险。
- 使用COX-2抑制剂的患者手法松解风险更低,术后90天阿片类药物消耗减少。
- 作者认为这些结果应谨慎解读,若考虑在抗凝患者中使用NSAID治疗,应密切监测。
研究设计与样本
- 使用行政索赔数据库回顾性分析2017至2021年232,542例初次全膝关节置换术患者。
- 队列中2,299例长期抗凝,其中508例术后处方塞来昔布或美洛昔康。
- 证据等级为LEVEL III:病例对照系列。
主要发现
- 联合使用NSAIDs与30、90、180天输血和再入院风险增加无关。
- 抗凝患者使用NSAIDs后90天阿片类药物处方填充减少9%(P=0.038),180天减少10%(P=0.040)。
关键数值与推荐
- 主要结局包括30天和90天输血率与再入院率、手法松解率、至180天再手术率,以及30、90、180天以口服吗啡当量衡量的阿片类药物消耗。
- 使用NSAIDs组90天阿片类药物处方填充减少9%(P=0.038),180天减少10%(P=0.040)。
临床怎么用
- 作者认为这些结果应谨慎解读。
- 作者提出若考虑在抗凝患者中使用NSAID治疗,应密切监测。
局限性
- 作者指出这些结果应谨慎解读。
- 作者提出若考虑在抗凝患者中使用NSAID治疗,应密切监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The nonsteroidal anti-inflammatory drugs (NSAIDs) are foundational components of multimodal pain protocols and have been shown to improve pain and range of motion following total knee arthroplasty (TKA). Patients receiving chronic anticoagulation therapy undergoing TKA are potentially disadvantaged because there are concerns with concurrent NSAID use due to bleeding concerns. Evidence suggests that cyclo-oxygenase 2 (Cox-2) inhibitors may not be associated with increased bleeding risk. The purpose of this study was to evaluate the safety of concurrent administration of NSAIDs in chronically anticoagulated patients undergoing primary TKA. METHODS: Using an administrative claims database, we reviewed the records of 232,542 patients undergoing TKA between 2017 and 2021. Within this cohort, there were 2,299 patients who were chronically anticoagulated and 508 patients who were prescribed either celecoxib or meloxicam following TKA. The outcomes of interest included 30- and 90-day transfusion and readmission rates, rates of manipulation, and reoperations up to 180 days, and 30-, 90-, and 180-day opioid consumption measured as oral morphine equivalents between the two groups. RESULTS: Concurrent administration of NSAIDs was not associated with increased risks for blood transfusions and readmissions at 30, 90, and 180 days. The administration of NSAIDs was associated with a decrease in manipulations without an increased risk for reoperations (odds ratio 0.48, confidence interval 0.28 to 0.82, P = 0.007). A modest reduction in 90 (9%, P = 0.038) and 180 (10%, P = 0.040) opioid prescriptions filled was observed in anticoagulated patients receiving NSAIDs following primary TKA. CONCLUSIONS: Concurrent administration of COX-2 NSAIDs in chronically anticoagulated patients undergoing primary TKA was not associated with increased transfusions or readmissions. Patients receiving COX-2 inhibitors had a lower risk of manipulation and reduced opioid consumption at 90 days postoperatively. These results should be interpreted with caution, and if considering NSAID therapy in anticoagulated patients, they should be closely monitored. LEVEL OF EVIDENCE: LEVEL III: Case Controlled Series.
引用
- Lee GC, Zhong H, Nocon A, et al. Is It Safe to Give Meloxicam or Celecoxib to Chronically Anticoagulated Patients Following Primary Total Knee Arthroplasty? J Arthroplasty. 2025. PMID: 41205719. doi:10.1016/j.arth.2025.10.115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。